Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan

Background: Understanding the prescribing patterns could better inform irritable bowel syndrome (IBS) management and health policy. However, there is no study on prescribing patterns of IBS in Taiwan. This study was conducted to evaluate the epidemiology, clinical features, and prescribing patterns...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Yu-Tung, Chen, Chung-Yu, Bair, Ming-Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717931/
https://www.ncbi.nlm.nih.gov/pubmed/34975485
http://dx.doi.org/10.3389/fphar.2021.788795
_version_ 1784624615041007616
author Lai, Yu-Tung
Chen, Chung-Yu
Bair, Ming-Jong
author_facet Lai, Yu-Tung
Chen, Chung-Yu
Bair, Ming-Jong
author_sort Lai, Yu-Tung
collection PubMed
description Background: Understanding the prescribing patterns could better inform irritable bowel syndrome (IBS) management and health policy. However, there is no study on prescribing patterns of IBS in Taiwan. This study was conducted to evaluate the epidemiology, clinical features, and prescribing patterns of IBS in Taiwan. Methods: This population-based cross-sectional study was performed by retrieving claim data from National Health Insurance Research Database (NHIRD) between 2011 and 2018 in Taiwan. Patients who were diagnosed with IBS during 2012–2018 and more than 20 years old were included. The annual incidence and prevalence of IBS were estimated. The characteristics and prescribing pattern were evaluated among IBS population. The population with IBS were followed from index date until 1 year after or death. Results: A total of 1691596 patients diagnosed with IBS were identified from 2012 to 2018. The average annual incidence and prevalence of IBS in Taiwan were calculated as 106.54 and 181.75 per 10,000 population. The incidence and prevalence showed a decreasing trend from 2012 to 2018. Hypertension, dyslipidemia, chronic liver disease, peptic ulcer, gastroesophageal reflux disease (GERD), anxiety, and sleep disorder were the prevalent comorbidities in IBS population. At 1 year after IBS diagnosis, the rates of peptic ulcer and GERD; the utilizations of abdominal ultrasonography, upper gastrointestinal (GI) endoscopy, and lower GI endoscopy; the prescribing rate of propulsives, simethicone, antacids, H2-blockers, and proton pump inhibitors significantly increased. Approximately 70% of participants received IBS-related treatment. Antispasmodics was the most frequently prescribed medication class, followed by laxatives and antidiarrheals. Only 48.58% of patients made return visit for IBS at 1 year after IBS diagnosis. Consequently, the proportion of consultation for IBS and the prescribing rates of all medications were decreased considerably after IBS diagnosis. Conclusion: The incidence and prevalence of IBS showed a decreasing trend from 2012 to 2018. More than two-third of patients received treatment for IBS. Antispasmodics was widely used for IBS management. However, patients may have a short symptom duration or receive a short course of IBS-related treatment in Taiwan. These findings provided the whole picture of the epidemiology and prescribing pattern of the IBS population in Taiwan.
format Online
Article
Text
id pubmed-8717931
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87179312021-12-31 Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan Lai, Yu-Tung Chen, Chung-Yu Bair, Ming-Jong Front Pharmacol Pharmacology Background: Understanding the prescribing patterns could better inform irritable bowel syndrome (IBS) management and health policy. However, there is no study on prescribing patterns of IBS in Taiwan. This study was conducted to evaluate the epidemiology, clinical features, and prescribing patterns of IBS in Taiwan. Methods: This population-based cross-sectional study was performed by retrieving claim data from National Health Insurance Research Database (NHIRD) between 2011 and 2018 in Taiwan. Patients who were diagnosed with IBS during 2012–2018 and more than 20 years old were included. The annual incidence and prevalence of IBS were estimated. The characteristics and prescribing pattern were evaluated among IBS population. The population with IBS were followed from index date until 1 year after or death. Results: A total of 1691596 patients diagnosed with IBS were identified from 2012 to 2018. The average annual incidence and prevalence of IBS in Taiwan were calculated as 106.54 and 181.75 per 10,000 population. The incidence and prevalence showed a decreasing trend from 2012 to 2018. Hypertension, dyslipidemia, chronic liver disease, peptic ulcer, gastroesophageal reflux disease (GERD), anxiety, and sleep disorder were the prevalent comorbidities in IBS population. At 1 year after IBS diagnosis, the rates of peptic ulcer and GERD; the utilizations of abdominal ultrasonography, upper gastrointestinal (GI) endoscopy, and lower GI endoscopy; the prescribing rate of propulsives, simethicone, antacids, H2-blockers, and proton pump inhibitors significantly increased. Approximately 70% of participants received IBS-related treatment. Antispasmodics was the most frequently prescribed medication class, followed by laxatives and antidiarrheals. Only 48.58% of patients made return visit for IBS at 1 year after IBS diagnosis. Consequently, the proportion of consultation for IBS and the prescribing rates of all medications were decreased considerably after IBS diagnosis. Conclusion: The incidence and prevalence of IBS showed a decreasing trend from 2012 to 2018. More than two-third of patients received treatment for IBS. Antispasmodics was widely used for IBS management. However, patients may have a short symptom duration or receive a short course of IBS-related treatment in Taiwan. These findings provided the whole picture of the epidemiology and prescribing pattern of the IBS population in Taiwan. Frontiers Media S.A. 2021-12-09 /pmc/articles/PMC8717931/ /pubmed/34975485 http://dx.doi.org/10.3389/fphar.2021.788795 Text en Copyright © 2021 Lai, Chen and Bair. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lai, Yu-Tung
Chen, Chung-Yu
Bair, Ming-Jong
Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan
title Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan
title_full Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan
title_fullStr Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan
title_full_unstemmed Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan
title_short Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan
title_sort epidemiology, clinical features, and prescribing patterns of irritable bowel syndrome in taiwan
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717931/
https://www.ncbi.nlm.nih.gov/pubmed/34975485
http://dx.doi.org/10.3389/fphar.2021.788795
work_keys_str_mv AT laiyutung epidemiologyclinicalfeaturesandprescribingpatternsofirritablebowelsyndromeintaiwan
AT chenchungyu epidemiologyclinicalfeaturesandprescribingpatternsofirritablebowelsyndromeintaiwan
AT bairmingjong epidemiologyclinicalfeaturesandprescribingpatternsofirritablebowelsyndromeintaiwan